Stage III ovarian cancer : 11 retrospective studies with 2,220 participants. One additional study was excluded from analyses because numbers were too small (17 participants).
Stage IV ovarian cancer: 4 retrospective studies with 422 participants.
The effects of residual disease on survival rates. ORs greater than 1 indicate a benefit for patients with residual disease of 2cm or smaller, compared with those with larger residuals. ORs for stage III cancer at 2 and 5 years were 3.98 (95% CI: 3.31, 4.79) and 5.51 (95% CI: 4.40, 6.90), respectively; for stage IV cancer at 2 years, OR was 4.94 (95% CI: 2.55, 9.57).
Comparing nil residuals with those of 2 cm or less, where an OR greater than 1 favours nil residual: ORs for stage III cancer at 2 and 5 years were 3.37 (95% CI: 2.17, 5.22) and 4.35 (95% CI: 2.87, 6.61), respectively.